Managing patients with myelofibrosis (MF), either those with primary MF or those whose MF
has evolved from antecedent polycythemia vera or essential thrombocythemia, presents …

The clinical phenotype of myelofibrosis (MF) is recognized either de novo (primary) or in the
setting of polycythemia vera (post‐PV) or essential thrombocythemia (post‐ET) …

Primary myelofibrosis (PMF) is a clonal stem cell disorder that manifests clinically as
anemia, splenomegaly due to extramedullary hematopoiesis, leukoerythroblastosis, and …

Abstract The Philadelphia chromosome‐negative (Ph−) chronic myeloproliferative disorders
(MPD) have an inherent tendency for transformation into acute myelogenous leukaemia …

Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders
characterized by proliferation of one or more myeloid cell lineages. Some patients exhibit …

Managing patients with myelofibrosis (MF)(both those with primary myelofibrosis or having
evolved from an antecedent polycythemia vera or essential thrombocythemia) present many …

Blast phase (BP) may occur as a late event in essential thrombocythemia (ET). This study
includes 19patients with post-ET BP diagnosed and followed in a single institution. At BP …

In the past 20 years, management of primary myelofibrosis (PMF) has incorporated new
treatment approaches, but survival benefits have not been confirmed in controlled studies …

Discussion PMF is very rare hematologic neoplasm in young patients. The patient described
here presented with a short history of constitutional symptoms and symptoms related to …